<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of hip osteoarthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of hip osteoarthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of hip osteoarthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leticia Alle Deveza, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jillian P Eyles, BAppSc (Physiotherapy), PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Hunter, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2246915417"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hip osteoarthritis (OA) is a prevalent disease that affects older adults and poses detrimental consequences on mobility and quality of life. Among those who will live until the age of 85 years, one in four will develop symptomatic hip OA [<a href="#rid1">1</a>]. Important risk factors for the disease, such as previous hip injury, occupations involving heavy physical activity, alterations in joint shape, and family history, may increase this risk substantially [<a href="#rid2">2</a>].</p><p>The management of hip OA is reviewed here. Separate pertinent topic reviews include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5498.html" rel="external">"Pathogenesis of osteoarthritis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5499.html" rel="external">"Epidemiology and risk factors for osteoarthritis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/105723.html" rel="external">"Clinical manifestations and diagnosis of osteoarthritis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106097.html" rel="external">"Overview of the management of osteoarthritis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7972.html" rel="external">"Total hip arthroplasty"</a>.)</p><p></p><p class="headingAnchor" id="H3657855376"><span class="h1">PRETREATMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H697048331"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Similar to the management of osteoarthritis (OA) in other joints, the management of hip OA involves a sequence of nonpharmacologic therapies followed by pharmacologic options aimed at relieving pain and improving function. When these interventions fail to alleviate symptoms and quality of life is compromised, eligible patients may be referred for total joint replacement. Other overall aspects of OA management, including patient education, self-management, and routine monitoring, are key treatment components that are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/106097.html" rel="external">"Overview of the management of osteoarthritis"</a>.)</p><p>Despite its significant societal burden, research regarding both the etiopathogenesis and treatment of hip OA has lagged far behind that of knee OA. Treatment recommendations for hip OA are often extrapolated from the knee, despite specific features of hip joint morphology that may affect which treatment may be appropriate. Among specific features, particular biomechanics and joint shape alterations are probably the most important drivers of the disease. Detection of early disease stages, particularly among patients with alterations in hip joint morphology, may help identify those who will benefit from earlier intervention since they may progress more rapidly.</p><p>Our management approach is generally consistent with guidelines developed by professional organizations [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H4188847178"><span class="h2">Assessment for alterations in hip joint morphology</span><span class="headingEndMark"> — </span>It is important to identify patients in the early stages of hip OA whose disease may be attributed to alterations in hip joint morphology [<a href="#rid6">6</a>]. These patients are typically younger and have milder symptoms; they may benefit from earlier intervention with activity modification and physical therapy (particularly in the case of athletes) and/or referral to an orthopedic surgeon for a possible joint-preserving surgical intervention. (See  <a class="medical medical_review" href="/d/html/5502.html" rel="external">"Overview of surgical therapy of knee and hip osteoarthritis", section on 'Hip osteotomy'</a>.)</p><p>Femoroacetabular impingement (FAI) and acetabular dysplasia are two abnormalities in hip morphology that are associated with the development of early-onset hip OA [<a href="#rid6">6</a>] (see  <a class="medical medical_review" href="/d/html/5499.html" rel="external">"Epidemiology and risk factors for osteoarthritis", section on 'Anatomic factors'</a>). The more prevalent of these shape alterations is FAI (see  <a class="medical medical_review" href="/d/html/100491.html" rel="external">"Approach to hip and groin pain in the athlete and active adult", section on 'Femoroacetabular impingement'</a>). These abnormalities are typically detected on hip radiographs. However, radiographic changes related to FAI are common in asymptomatic individuals [<a href="#rid7">7</a>]; thus, routine screening with radiographs in the absence of suggestive symptoms is not indicated.</p><p class="headingAnchor" id="H814693843"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1506399096"><span class="h2">Initial approach</span><span class="headingEndMark"> — </span>Nonpharmacologic measures, including education and support for self-management, exercise, and weight control, should be part of the initial approach for all patients with symptomatic hip osteoarthritis (OA) regardless of the severity of symptoms.</p><p class="headingAnchor" id="H4289992686"><span class="h3">Nonpharmacologic measures</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions for the management of patients with hip OA include exercise, walking aids, and, when pertinent, weight loss (<a class="graphic graphic_algorithm graphicRef121638" href="/d/graphic/121638.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1361310610"><span class="h4">Exercise</span><span class="headingEndMark"> — </span>In all patients with hip OA, we suggest ongoing exercise for reduction of pain and improvement in physical function. No particular activity type has been shown to produce overwhelmingly superior results; thus, exercise programs should be personalized to reflect the unique needs and preferences of each patient [<a href="#rid8">8</a>]. Some of the exercise modalities typically used for hip OA include aerobic exercise, flexibility exercises to improve range of motion, strengthening exercises, and tai chi.</p><p>Limited evidence suggests that exercise confers modest improvements in pain and function regardless of content, duration, intensity, or frequency [<a href="#rid9">9,10</a>]. In a Cochrane review including data from 9 trials with 549 patients with hip OA, land-based exercise (eg, functional training and aerobic fitness programs) resulted in reduced pain (standardized mean difference [SMD] -0.38, 95% CI -0.55 to -0.20) and improved physical function (SMD -0.38, 95% CI -0.54 to -0.05) immediately after treatment [<a href="#rid10">10</a>]. The reduction in pain and improvement in physical function translated to a reduction of 8 and 7 points, respectively, on a patient-reported visual analogue scale (0 to 100 points). Although generally favorable, there is less available evidence demonstrating the benefits of water-based exercise. A meta-analysis including 19 studies also reported short-term improvement in pain associated with hip OA for both land- and water-based exercises compared with a minimal intervention control [<a href="#rid9">9</a>]. Only four of the trials included water-based exercises, for which the pooled effect size was comparable to that of land-based exercise. The authors also point to additional theoretical benefits in which the buoyancy offered by the aquatic environment reduces weightbearing forces sustained by the lower limbs. This unloading of the hip joints may assist with pain relief. Water-based exercise in a heated pool has been anecdotally reported as providing additional pain relief. Although water-based exercise is potentially suitable for all individuals with hip OA, it may be especially preferable for those whose severe symptoms limit their ability to engage in land-based exercise.</p><p>We typically refer patients to physical therapy, particularly in circumstances where there is hip weakness, stiffness, or significant functional deficits [<a href="#rid11">11</a>]. Physical therapy for hip OA usually involves comprehensive assessment, an individualized exercise program, and adjunctive therapies such as walking aid prescription and manual therapies. The value of physical therapy for hip OA is controversial, with some evidence suggesting it offers little benefit beyond what could be expected from a self-guided exercise program [<a href="#rid12">12</a>]. One well-designed randomized trial compared 49 participants who received education and advice, manual therapy, a home exercise program, and walking aid (if appropriate) with 53 who received a sham treatment (inactive ultrasound and application of inert gel) [<a href="#rid13">13</a>]. The physical therapy group did not demonstrate statistically significant improvements in pain and function compared with the sham group. Two systematic reviews reported that the best available evidence does not support manual therapy for hip OA [<a href="#rid9">9,14</a>]; however, very few trials were available, and more are required to confirm these results. Despite the limited evidence available to support physical therapy treatments, in practice, people with hip OA may choose to consult with physical therapists for specific exercise prescription, advice on physical activity, and mobility problems.</p><p class="headingAnchor" id="H3849657717"><span class="h4">Walking aids</span><span class="headingEndMark"> — </span>Walking aids such as a cane (on the contralateral or unaffected side), a walker, or crutches may be used as needed for hip OA [<a href="#rid15">15</a>]. Situations in which walking aids may be appropriate may include the presence of severe lower limb joint pain or an increased risk of falling. While there are no data in support of the benefits of walking aids for hip OA, there is limited evidence that the use of a daily cane can reduce pain in patients with knee OA. (See  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Walking aids'</a>.)</p><p class="headingAnchor" id="H1459139417"><span class="h4">Weight loss</span><span class="headingEndMark"> — </span>We generally advise that patients with hip OA who are overweight or obese lose weight. This suggestion is largely based on indirect evidence from knee OA, as there are no trials demonstrating the benefits of weight loss for hip OA [<a href="#rid3">3,16</a>]. Obesity is also a known risk factor for hip OA and is associated with more severe disease [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Weight loss'</a> and  <a class="medical medical_review" href="/d/html/5499.html" rel="external">"Epidemiology and risk factors for osteoarthritis", section on 'Obesity'</a>.)</p><p>We encourage health care professionals to consult available local community programs or refer patients to a dietitian to ensure that patients with obesity or who are overweight are offered optimal support to lose weight. (See  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p class="headingAnchor" id="H3074845657"><span class="h3">Pharmacologic measures</span><span class="headingEndMark"> — </span>Pharmacologic therapies can be used in concert with nonpharmacologic measures for patients with more constant and disabling pain, or after a trial of nonpharmacologic measures if no appropriate pain relief is achieved in around three months (<a class="graphic graphic_algorithm graphicRef121638" href="/d/graphic/121638.html" rel="external">algorithm 1</a>). In our clinical practice, we recommend ongoing exercises even in patients with no or little clinical benefits after a three-month exercise trial led by a physical therapist.</p><p class="headingAnchor" id="H3200343242"><span class="h4">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>For patients with hip OA who have had insufficient relief with nonpharmacologic measures, we suggest oral nonsteroidal anti-inflammatory drugs (NSAIDs), preferably on an as-needed basis. The efficacy of nonselective NSAIDs and cyclooxygenase (COX)-2 inhibitors (coxibs) compared with placebo has been demonstrated in the treatment of hip OA (mainly with respect to pain relief) in randomized trials of individual drugs and in meta-analyses of randomized trials [<a href="#rid18">18,19</a>]. A network meta-analysis of randomized trials comparing NSAIDs with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or placebo for the treatment of pain for either hip or knee OA found that all of the NSAIDs included in the analysis improved point estimates of pain symptoms when compared with placebo or acetaminophen [<a href="#rid18">18</a>].</p><p>In light of their potential adverse effects, including gastrointestinal ulcers, cardiovascular disease, and renal damage, chronic NSAID use should generally be avoided. We administer oral NSAIDs in the lowest dose and duration possible in patients without contraindications who have substantial symptoms and inadequate response to nonpharmacologic measures. The use of oral NSAIDs as needed is preferred to fixed daily doses for patients with less severe symptoms. The different types of NSAIDs, doses, and adverse effects are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Oral NSAIDs'</a>.)</p><p class="headingAnchor" id="H4288129218"><span class="h4">Limited role of intraarticular glucocorticoids</span><span class="headingEndMark"> — </span>We suggest against the routine use of intraarticular glucocorticoid injections for patients with hip OA. We limit the use of intraarticular glucocorticoid injection to patients with moderate to severe hip pain when short-term pain relief is desired and there are contraindications to, or failure of, other treatment alternatives. Image guidance (eg, with ultrasound or, less commonly, fluoroscopy) is usually required for intraarticular hip injections due to technical difficulties owing to the joint's depth and proximity to the femoral vessels.</p><p>There are fewer trials assessing the efficacy of intraarticular glucocorticoids for hip OA compared with knee OA. A systematic review including five relatively small trials found that an intraarticular glucocorticoid injection has moderate effects on pain up to eight weeks post injection compared with placebo [<a href="#rid20">20</a>]. In a larger trial including 199 patients with moderate pain from hip OA, patients were randomly assigned to receive advice and education, advice and education plus an ultrasound-guided injection of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> and <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, or advice and education plus an ultrasound-guided injection of lidocaine alone [<a href="#rid21">21</a>]. Patients in the advice and education plus ultrasound-triamcinolone-lidocaine arm reported greater improvement on a 0 to 10 numeric rating scale of overall hip pain intensity over six months compared with advice and education alone (mean difference -1.43 [95% CI -2.15 to -0.72]). A greater mean improvement was detected at two weeks and two months, but not at four or six months. Hip pain intensity scores were similar in both of the ultrasound-guided injection groups; thus, a placebo response associated with the injections cannot be excluded. Otherwise, there is a paucity of long-term data, and the benefits of glucocorticoid injections appear to be limited after eight weeks. (See  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Limited role of intraarticular glucocorticoid injections'</a>.)</p><p>A single trial investigated the effects of intramuscular injection of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetate compared with placebo for patients with persistent pain from hip OA despite the use of oral analgesics [<a href="#rid22">22</a>]. This trial was conducted to investigate a potential alternative method for glucocorticoid administration due to the inherent difficulties associated with intraarticular hip injections such as the need for imaging guidance. There were improvements in pain (difference -1.3, 95% CI -2.3 to -0.3, on a 0 to 10 numeric rating scale) and function up to 12 weeks in the group that received triamcinolone. It is important to note that systemic administration of glucocorticoids via the intramuscular route presents increased risks of systemic side effects such as hyperglycemia in patients with diabetes and is not routinely performed in most clinical practices for patients with hip OA. More data are needed before intramuscular glucocorticoid injections are offered as an alternative to intraarticular injections.</p><p>Limited data also suggest that intraarticular glucocorticoid injections in the hip may be associated with an increased risk of rapidly destructive hip disease (RDHD), characterized as rapidly progressive joint space narrowing, osteolysis, and collapse of the femoral head [<a href="#rid23">23-27</a>]. In a case-control study comparing 40 patients with RDHD with 717 controls who underwent total hip arthroplasty for OA, at least 1 intraarticular glucocorticoid injection was associated with a higher risk of RDHD (odds ratio 8.56, 95% CI 3.29-22.3) [<a href="#rid23">23</a>]. A dose-response effect was also observed, in which the risk of RDHD was higher with increasing the injection dose as well as the number of injections received. Post-injection RDHD was diagnosed radiographically at an average of 5.1 months after injection. RDHD and other complications associated with intraarticular joint injections are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7977.html" rel="external">"Joint aspiration or injection in adults: Complications"</a>.)</p><p class="headingAnchor" id="H7878534"><span class="h2">Refractory symptoms</span></p><p class="headingAnchor" id="H3541688587"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>We refer patients for surgical evaluation when they have not improved after a trial of nonpharmacologic and pharmacologic options, have advanced structural hip OA, and have substantial symptoms impacting their quality of life (<a class="graphic graphic_algorithm graphicRef121638" href="/d/graphic/121638.html" rel="external">algorithm 1</a>). Total hip arthroplasty, which is the most common surgical procedure for hip OA, is associated with excellent short- and long-term clinical outcomes when patient selection for surgery is appropriate [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7972.html" rel="external">"Total hip arthroplasty"</a> and  <a class="medical medical_review" href="/d/html/5502.html" rel="external">"Overview of surgical therapy of knee and hip osteoarthritis"</a>.)</p><p class="headingAnchor" id="H2319071343"><span class="h1">THERAPIES LACKING EFFICACY OR OF UNCERTAIN BENEFIT</span><span class="headingEndMark"> — </span>There are several approaches that have been used as adjunctive measures to treat patients with hip osteoarthritis (OA) that we do not routinely recommend due to the lack of data demonstrating efficacy. In addition, there are other therapies in which the benefit remains uncertain. We discuss a few of these alternative therapies along with the limited available evidence below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duloxetine</strong> – Although <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> may be used as a therapeutic option for moderate to severe knee OA, there are limited data regarding the use of this agent in the context of hip OA. In an open-label randomized trial including patients with chronic hip or knee OA, 132 patients were administered either duloxetine plus usual care or duloxetine alone [<a href="#rid29">29</a>]. There were no statistically significant differences in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores between the groups at 3 or 12 months. However, limitations to the trial include the high dropout rate, the fact that many participants in the intervention group stopped taking duloxetine, and that only 24 participants reported that their most affected joint was the hip. More data are needed regarding its effects on hip OA before routine use of this medication can be suggested for patients with moderate to severe hip OA. Nevertheless, due to the presumed similar pain mechanisms between patients with moderate to severe knee and hip OA, a trial of duloxetine may be reasonable when clinically appropriate. (See  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Duloxetine'</a> and  <a class="medical medical_review" href="/d/html/106097.html" rel="external">"Overview of the management of osteoarthritis", section on 'Mechanisms of pain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucosamine and chondroitin</strong> – There is insufficient evidence to support the regular use of glucosamine and chondroitin for hip OA. Only one trial investigated the effects of glucosamine on symptoms and radiographic progression in 222 patients with hip OA and found no benefits over placebo [<a href="#rid30">30</a>]. Many more trials have been performed to evaluate the effects on knee OA, the results of which are conflicting and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Nutritional supplements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acetaminophen</strong> – Due to safety concerns related to <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (paracetamol) use and emerging evidence of its limited effects on pain, we do not initiate treatment with acetaminophen for hip OA in our clinical practice [<a href="#rid31">31</a>]. A more detailed discussion of the limited efficacy of acetaminophen for knee OA can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Acetaminophen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyaluronans</strong> – The use of any intraarticular <a class="drug drug_general" data-topicid="8643" href="/d/drug information/8643.html" rel="external">hyaluronic acid</a> (HA) formulation for hip OA is generally not recommended due to the lack of robust evidence demonstrating benefit. As with trials in knee OA, trials assessing the efficacy of intraarticular HAs for hip OA have found little to no benefit over placebo [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Hyaluronans'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture</strong> – Limited data suggest that acupuncture has limited to no effect on pain and function in patients with hip OA. A Cochrane meta-analysis found that acupuncture has little or no effect on pain and function in hip OA in the short term based on data from two trials with moderate-quality evidence [<a href="#rid36">36</a>]. There was a small number of participants included in the analysis (105 participants), and the estimates were not precise, suggesting that further research is needed. A single, unblinded trial found clinically significant improvements in clinical outcomes at 12 weeks in participants randomly assigned to acupuncture added to usual primary care compared with usual care alone [<a href="#rid37">37</a>]. Acupuncture is conditionally recommended for treatment of hip OA in the 2019 American College of Rheumatology guideline [<a href="#rid4">4</a>] but has not been included in the 2019 Osteoarthritis Research Society International (OARSI) guideline [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet-rich plasma injections</strong> – Due to the limited evidence supporting the efficacy of platelet-rich plasma (PRP) injections for hip OA, we do not recommend their use [<a href="#rid38">38</a>]. A meta-analysis of randomized trials comparing PRP injections with HA found that intraarticular injection with PRP was associated with a reduction in patient-reported pain scores at two months, which were not present at 6 and 12 months [<a href="#rid39">39</a>]. However, these findings are limited due to the small sample sizes, the variability between trials including the different preparations of the PRP, and the lack of placebo as a comparator.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids</strong> – Given the relatively high incidence of adverse effects associated with opioid analgesics, we avoid the use of opioids whenever possible. In addition to safety concerns, there is also evidence that opioids lack clinically meaningful benefits for knee and hip OA patients [<a href="#rid40">40-42</a>]. A randomized trial that included 240 patients with severe chronic back pain or hip or knee OA found that the effects on pain-related function over 12 months was similar between the opioid and nonopioid group, with more adverse medication-related effects in the opioid group [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Opioids'</a>.)</p><p></p><p class="headingAnchor" id="H2582554641"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113788.html" rel="external">"Society guideline links: Osteoarthritis"</a>.)</p><p class="headingAnchor" id="H65775328"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Similar to the management of osteoarthritis (OA) in other joints, the management of hip OA involves a sequence of nonpharmacologic therapies followed by pharmacologic options aimed at relieving pain and improving function (<a class="graphic graphic_algorithm graphicRef121638" href="/d/graphic/121638.html" rel="external">algorithm 1</a>). Despite its significant societal burden, research regarding hip OA has lagged far behind that of knee OA. Treatment recommendations for hip OA are often extrapolated from the knee, despite specific features of hip joint morphology that may affect which treatment may be appropriate. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is important to identify patients in the early stages of hip OA whose disease may be attributed to alterations in hip joint morphology, as they may benefit from earlier intervention with activity modification and physical therapy and/or referral to an orthopedic surgeon for a possible joint-preserving surgical intervention. Femoroacetabular impingement (FAI) and acetabular dysplasia are two abnormalities in hip morphology that are associated with the development of early-onset hip OA. (See <a class="local">'Assessment for alterations in hip joint morphology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients with hip OA, we suggest ongoing exercise for reduction of pain and improvement in physical function (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). No particular type of activity has been shown to produce overwhelmingly superior results; thus, exercise programs should be personalized to reflect the unique needs and preferences of each patient. (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Walking aids such as a cane (in the contralateral or unaffected side), walker, or crutches may be used as needed for hip OA. While there are no data in support of the benefits of walking aids for hip OA, there is limited evidence from patients with knee OA that the use of a daily cane can reduce pain. (See <a class="local">'Walking aids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally advise that patients with hip OA who are overweight or obese lose weight. This suggestion is largely based on indirect evidence from knee OA as no trials have evaluated the effects of weight loss on hip OA. Obesity is also a known risk factor for hip OA and is associated with more severe disease. (See <a class="local">'Weight loss'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hip OA who have had insufficient relief with nonpharmacologic measures, we suggest oral nonsteroidal anti-inflammatory drugs (NSAIDs) rather than <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, preferably on an as-needed basis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The choice of NSAID is based on a variety of factors including adverse effect profile, patient comorbidities, cost to patient, and patient preference regarding frequency of administration. (See <a class="local">'Nonsteroidal anti-inflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest against the routine use of intraarticular glucocorticoid injections for patients with hip OA (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We limit the use of injections to patients with moderate to severe hip pain when short-term pain relief is desired and there are contraindications to, or failure of, other treatment alternatives. Image guidance (eg, with ultrasound or, less commonly, fluoroscopy) is usually required for intraarticular hip injections due to technical difficulties owing to the joint's depth and proximity to the femoral vessels. (See <a class="local">'Limited role of intraarticular glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We refer patients for surgical evaluation when they have not improved after a trial of nonpharmacologic and pharmacologic options, have advanced structural OA, and have substantial symptoms impacting their quality of life. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several approaches that have been used to treat patients with hip OA that we do not routinely recommend due to the lack of data demonstrating efficacy. In addition, there are other therapies in which the benefit remains uncertain. Examples of such therapies include <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, glucosamine and chondroitin, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, hyaluronans, acupuncture, platelet-rich plasma (PRP) injections, and opioids. (See <a class="local">'Therapies lacking efficacy or of uncertain benefit'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Murphy LB, Helmick CG, Schwartz TA, et al. One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage 2010; 18:1372.</a></li><li><a class="nounderline abstract_t">Murphy NJ, Eyles JP, Hunter DJ. Hip Osteoarthritis: Etiopathogenesis and Implications for Management. Adv Ther 2016; 33:1921.</a></li><li><a class="nounderline abstract_t">Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013; 72:1125.</a></li><li><a class="nounderline abstract_t">Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken) 2020; 72:149.</a></li><li><a class="nounderline abstract_t">Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27:1578.</a></li><li><a class="nounderline abstract_t">Sandell LJ. Etiology of osteoarthritis: genetics and synovial joint development. Nat Rev Rheumatol 2012; 8:77.</a></li><li><a class="nounderline abstract_t">Frank JM, Harris JD, Erickson BJ, et al. Prevalence of Femoroacetabular Impingement Imaging Findings in Asymptomatic Volunteers: A Systematic Review. Arthroscopy 2015; 31:1199.</a></li><li><a class="nounderline abstract_t">Gay C, Chabaud A, Guilley E, Coudeyre E. Educating patients about the benefits of physical activity and exercise for their hip and knee osteoarthritis. Systematic literature review. Ann Phys Rehabil Med 2016; 59:174.</a></li><li><a class="nounderline abstract_t">Beumer L, Wong J, Warden SJ, et al. Effects of exercise and manual therapy on pain associated with hip osteoarthritis: a systematic review and meta-analysis. Br J Sports Med 2016; 50:458.</a></li><li><a class="nounderline abstract_t">Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev 2014; :CD007912.</a></li><li><a class="nounderline abstract_t">Meneses SR, Goode AP, Nelson AE, et al. Clinical algorithms to aid osteoarthritis guideline dissemination. Osteoarthritis Cartilage 2016; 24:1487.</a></li><li><a class="nounderline abstract_t">Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol 2015; 27:304.</a></li><li><a class="nounderline abstract_t">Bennell KL, Egerton T, Martin J, et al. Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial. JAMA 2014; 311:1987.</a></li><li><a class="nounderline abstract_t">Wang Q, Wang TT, Qi XF, et al. Manual Therapy for Hip Osteoarthritis: A Systematic Review and Meta-analysis. Pain Physician 2015; 18:E1005.</a></li><li><a class="nounderline abstract_t">Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum 2014; 43:701.</a></li><li><a class="nounderline abstract_t">Salis Z, Sainsbury A. Association of Change in Body Mass Index With Incidence and Progression of the Structural Defects of Hip Osteoarthritis: Data From the Osteoarthritis Initiative and the Cohort Hip and Cohort Knee study. Arthritis Care Res (Hoboken) 2023; 75:1527.</a></li><li><a class="nounderline abstract_t">Jiang L, Rong J, Wang Y, et al. The relationship between body mass index and hip osteoarthritis: a systematic review and meta-analysis. Joint Bone Spine 2011; 78:150.</a></li><li><a class="nounderline abstract_t">da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017; 390:e21.</a></li><li><a class="nounderline abstract_t">Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; :CD004257.</a></li><li><a class="nounderline abstract_t">McCabe PS, Maricar N, Parkes MJ, et al. The efficacy of intra-articular steroids in hip osteoarthritis: a systematic review. Osteoarthritis Cartilage 2016; 24:1509.</a></li><li><a class="nounderline abstract_t">Paskins Z, Bromley K, Lewis M, et al. Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ 2022; 377:e068446.</a></li><li><a class="nounderline abstract_t">Dorleijn DMJ, Luijsterburg PAJ, Reijman M, et al. Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial. Ann Rheum Dis 2018; 77:875.</a></li><li><a class="nounderline abstract_t">Okike K, King RK, Merchant JC, et al. Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip. J Bone Joint Surg Am 2021; 103:2070.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Schneider R, Iwamoto Y, Bullough PG. Rapid destruction of the femoral head after a single intraarticular injection of corticosteroid into the hip joint. J Rheumatol 2006; 33:1701.</a></li><li><a class="nounderline abstract_t">Ahmed AF, Hammad M, Salameh M, Ahmed GO. Destructive Osteonecrosis of the Femoral Head After a Single Intra-Articular Corticosteroid Injection: A Report of Two Cases. Int J Surg Case Rep 2020; 77:711.</a></li><li><a class="nounderline abstract_t">Thompson AR, Ensrud ER. Rapid Onset of Femoral Head Osteonecrosis After a Single Intra-articular Hip Joint Injection of Corticosteroid. Am J Phys Med Rehabil 2020; 99:e54.</a></li><li><a class="nounderline abstract_t">Kompel AJ, Roemer FW, Murakami AM, et al. Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought? Radiology 2019; 293:656.</a></li><li><a class="nounderline abstract_t">Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. Lancet 2012; 380:1768.</a></li><li><a class="nounderline abstract_t">van den Driest JJ, Schiphof D, Koffeman AR, et al. No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A Cluster-Randomized Trial. Arthritis Rheumatol 2022; 74:818.</a></li><li><a class="nounderline abstract_t">Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008; 148:268.</a></li><li><a class="nounderline abstract_t">Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350:h1225.</a></li><li><a class="nounderline abstract_t">Brander V, Skrepnik N, Petrella RJ, et al. Evaluating the use of intra-articular injections as a treatment for painful hip osteoarthritis: a randomized, double-blind, multicenter, parallel-group study comparing a single 6-mL injection of hylan G-F 20 with saline. Osteoarthritis Cartilage 2019; 27:59.</a></li><li><a class="nounderline abstract_t">Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage 2006; 14:163.</a></li><li><a class="nounderline abstract_t">Richette P, Ravaud P, Conrozier T, et al. Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. Arthritis Rheum 2009; 60:824.</a></li><li><a class="nounderline abstract_t">Atchia I, Kane D, Reed MR, et al. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis 2011; 70:110.</a></li><li><a class="nounderline abstract_t">Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for hip osteoarthritis. Cochrane Database Syst Rev 2018; 5:CD013010.</a></li><li><a class="nounderline abstract_t">Witt CM, Jena S, Brinkhaus B, et al. Acupuncture in patients with osteoarthritis of the knee or hip: a randomized, controlled trial with an additional nonrandomized arm. Arthritis Rheum 2006; 54:3485.</a></li><li><a class="nounderline abstract_t">Bennell KL, Hunter DJ, Paterson KL. Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis. Curr Rheumatol Rep 2017; 19:24.</a></li><li><a class="nounderline abstract_t">Ye Y, Zhou X, Mao S, et al. Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg 2018; 53:279.</a></li><li><a class="nounderline abstract_t">da Costa BR, Nüesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2014; :CD003115.</a></li><li><a class="nounderline abstract_t">Megale RZ, Deveza LA, Blyth FM, et al. Efficacy and Safety of Oral and Transdermal Opioid Analgesics for Musculoskeletal Pain in Older Adults: A Systematic Review of Randomized, Placebo-Controlled Trials. J Pain 2018; 19:475.e1.</a></li><li><a class="nounderline abstract_t">Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA 2018; 319:872.</a></li></ol></div><div id="topicVersionRevision">Topic 119317 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713163" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : One in four people may develop symptomatic hip osteoarthritis in his or her lifetime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671326" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hip Osteoarthritis: Etiopathogenesis and Implications for Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23595142" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908149" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31278997" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231237" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Etiology of osteoarthritis: genetics and synovial joint development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636988" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of Femoroacetabular Impingement Imaging Findings in Asymptomatic Volunteers: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053003" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Educating patients about the benefits of physical activity and exercise for their hip and knee osteoarthritis. Systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26612846" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of exercise and manual therapy on pain associated with hip osteoarthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24756895" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Exercise for osteoarthritis of the hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095418" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical algorithms to aid osteoarthritis guideline dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25775185" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Physical therapies in the management of osteoarthritis: current state of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846036" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606015" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Manual Therapy for Hip Osteoarthritis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24387819" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36354244" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of Change in Body Mass Index With Incidence and Progression of the Structural Defects of Hip Osteoarthritis: Data From the Osteoarthritis Initiative and the Cohort Hip and Cohort Knee study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580591" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The relationship between body mass index and hip osteoarthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28699595" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acetaminophen for osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143362" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The efficacy of intra-articular steroids in hip osteoarthritis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35387783" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514801" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34550909" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16881128" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rapid destruction of the femoral head after a single intraarticular injection of corticosteroid into the hip joint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33395881" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Destructive Osteonecrosis of the Femoral Head After a Single Intra-Articular Corticosteroid Injection: A Report of Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32195718" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rapid Onset of Femoral Head Osteonecrosis After a Single Intra-articular Hip Joint Injection of Corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31617798" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021846" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34989159" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A Cluster-Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283204" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828856" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30223023" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluating the use of intra-articular injections as a treatment for painful hip osteoarthritis: a randomized, double-blind, multicenter, parallel-group study comparing a single 6-mL injection of hylan G-F 20 with saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16290043" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248105" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068096" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29729027" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acupuncture for hip osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075849" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acupuncture in patients with osteoarthritis of the knee or hip: a randomized, controlled trial with an additional nonrandomized arm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28386761" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29626641" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25229835" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Oral or transdermal opioids for osteoarthritis of the knee or hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241834" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and Safety of Oral and Transdermal Opioid Analgesics for Musculoskeletal Pain in Older Adults: A Systematic Review of Randomized, Placebo-Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509867" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
